As of Friday close, Organon & Co.’s (NYSE:OGN) stock was down -$0.05, moving down -0.23 percent to $21.67. The average number of shares traded per day over the past five days has been 3,066,360 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.01 fall in that time frame. In the last twenty days, the average volume was 2,680,410, while in the previous 50 days, it was 2,283,772.
Since last month, OGN stock retreated -25.94%. Shares of the company fell to $21.11 on 03/15/23, the lowest level in the past month. A 52-week high of $39.09 was reached on 01/18/23 after having rallying from a 52-week low of $21.11. Since the beginning of this year, OGN’s stock price has dropped by -22.41% or -$6.26, and marked a new high 10 times. However, the stock has declined by -44.56% since its 52-week high.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Valuation Metrics
The latest dividend of $0.28 per share was paid out, remained unchanged from last year’s $0.28.
Financial Health
In the three months ended December 30, Organon & Co.’s quick ratio stood at 1.20, while its current ratio was 1.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 63.00% percent. In the year ended December 30, operating margins totaled 18.20%. Based on annual data, OGN earned $3.88 billion in gross profit and brought in $6.17 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 11.40%. Return on equity (ROE) for the past 12 months was -84.40%.
In Organon & Co.’s quarter-end financial report for December 30, it reported total debt of $8.9 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. OGN’s revenue fell -7.95% to $1.54 billion during the quarter, while net income inched up to $1.49 billion. While analysts expected Organon & Co. to report $0.9 quarterly earnings, the actual figure was $0.81 per share. During the quarter, the company generated $390.0 million in EBITDA. The liabilities of Organon & Co. were 11.85 billion at the end of its most recent quarter ended December 30, and its total debt was $9.11 billion. The value of shareholders’ equity is $254.38 million.
Technical Picture
This quick technical analysis looks at Organon & Co.’s (OGN) price momentum. With a historical volatility rate of 13.37%, the RSI 9-day stood at 18.93% on 17 March.
With respect to its five-day moving average, the current Organon & Co. price is down by -4.45% percent or -$1.01. At present, OGN shares trade -12.87% below its 20-day simple moving average and -8.49% percent below its 100-day simple moving average. However, the stock is currently trading approximately -25.12% below its SMA50 and -42.91% below its SMA200.
Stochastic coefficient K was 11.33% and Stochastic coefficient D was 7.83%, while ATR was 0.75. Given the Stochastic reading of 13.83% for the 14-day period, the RSI (14) reading has been calculated as 23.16%. As of today, the MACD Oscillator reading stands at -0.86, while the 14-day reading stands at -1.51.
Analyst Ratings
Raymond James launched its rating on Organon & Co. (NYSE: OGN) to an Outperform in a note to investors on March 16, 2023. Organon & Co. (OGN) has been rated Overweight by analysts. According to 0 brokerage firms, OGN is a sell, and 4 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Organon & Co. stock as buy, with 5 recommending it as overweight.
With a median target price of $33.00, the current consensus forecast for the stock is $24.00 – $43.00. Based on these forecasts, analysts predict Organon & Co. (OGN) will achieve an average price target of $32.89.